CRY1失调损害脑甲状腺激素通路并促进雄性小鼠焦虑样行为

Dysregulation of CRY1 impairs brain thyroid hormone pathway and promotes anxiety-like behavior in male mice

作者信息Baojiang Lv, Yuanyuan Liu, Yu Yang, Yedi Wu, Zhengxin Chen, Tianpeng Zhang, Fangjun Yu, Yafei Shi
PMID40334908
发布时间2025-08
DOI10.1016/j.metabol.2025.156292

实验完整度

包含基因敲除小鼠模型、慢性束缚应激模型、行为学测试、分子机制验证(Western blot、qPCR、ChIP、荧光素酶报告基因)及体外细胞实验等多个证据层级,功能验证和机制验证明确。

主要模型

Cry1基因敲除小鼠(Cry1-/-) 慢性束缚应激(CRS)诱导的焦虑小鼠模型 HT-22小鼠海马神经元细胞系 SH-SY5Y人神经母细胞瘤细胞系

重点核对

Cry1基因敲除小鼠的基因型验证(PCR) KL201给药剂量(5 mg/kg)及给药时间(ZT10) 慢性束缚应激持续时间(2小时/天,连续10天) T3补充剂量(0.1 mg/kg)及给药时间(连续7天) 行为学测试顺序及条件

摘要

Background: The circadian clock system plays a crucial role in influencing mood and behavior, with the clock gene Cry1 serving as a core component of the molecular circadian clock. However, the role of CRY1 in anxiety-related behaviors and their underlying mechanisms are poorly understood. Methods and results: In this study, we investigated the role of CRY1 in anxiety-related behaviors through various behavioral approaches, and assessed potential molecular alterations in key brain regions involved in behavioral responses. We found that male Cry1-/- (Cry1 knockout) mice developed anxiety-like behavior in both stressed and non-stressed conditions. Administration of CRY1 stabilizer KL201 significantly alleviated anxiety-like behavior in male mice. Further studies suggested involvement of the brain thyroid hormone signaling in CRY1 regulation of anxiety-like behavior, evidenced by markedly reduced brain T3 levels relation to down-regulation of OATP1C1 and DIO2 mediated by CRY1, which underlies neurogenesis deficits and contributes to anxiety. Subsequent in vivo and cell-based experiments confirmed that CRY1 positively regulates the expression of OATP1C1 and DIO2. Mechanistically, CRY1 regulates OATP1C1 and DIO2 through regulating the transcriptional activity of E4BP4. E4BP4 trans-inactivates OATP1C1 and DIO2 via direct binding to its specific response element in the gene promoters. Conclusion: These findings underscore the critical role of CRY1 in regulating thyroid hormone and anxiety, providing insight into the underlying pathogenesis and potential treatment strategies for mood disorders.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
CRY1在焦虑样行为中的角色及其潜在的分子机制是什么?
核心机制
CRY1通过抑制E4BP4的转录抑制活性,上调OATP1C1和DIO2的表达,从而增加脑内活性T3水平,促进神经发生,缓解焦虑样行为。
主要证据
Cry1敲除小鼠表现出焦虑样行为,伴随脑内T3水平降低、OATP1C1和DIO2表达下调;KL201激活CRY1或补充T3可改善焦虑表型;体外和体内实验证实CRY1通过E4BP4调控OATP1C1和DIO2。
研究意义
揭示CRY1在调节甲状腺激素和焦虑中的关键作用,为情绪障碍的病理机制提供见解,并为焦虑症的治疗提供潜在策略。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

建立焦虑模型并检测CRY1表达变化

确定CRY1是否与焦虑样行为相关

使用慢性束缚应激(CRS)诱导雄性野生型小鼠产生焦虑样行为,通过行为学测试(EPM、OFT、MBB、LDB)验证模型;随后检测海马组织中核心时钟基因的mRNA和蛋白表达,发现Cry1下调。

2

利用Cry1敲除小鼠验证焦虑表型

评估CRY1缺失对先天性和应激诱导的焦虑样行为的影响

对Cry1-/-和野生型小鼠进行一系列行为学测试(EPM、OFT、MBB、LDB、FCT),并检测海马中BDNF、CREB等基因表达和神经元损伤(Nissl染色、c-Fos免疫荧光)。

3

检测CRY1对脑甲状腺激素通路的影响

探究CRY1是否通过调节甲状腺激素信号通路影响焦虑

测量Cry1-/-和WT小鼠血清及海马中T3、T4、TSH水平;检测甲状腺激素转运体(OATP1C1、MCT8)和脱碘酶(DIO2、DIO3)的表达;评估T3下游靶基因(RC3、Aldh1a1、Hr)及神经发生标志物(Ki67、SOX2)。

4

体外验证CRY1对OATP1C1和DIO2的调控

确认CRY1是否直接调控OATP1C1和DIO2的表达

在HT-22和SH-SY5Y细胞中,通过siRNA敲低或质粒过表达CRY1,检测OATP1C1和DIO2的mRNA和蛋白水平;在C8-D1A星形胶质细胞中进行验证。

5

探究CRY1调控OATP1C1和DIO2的分子机制

阐明CRY1调控OATP1C1和DIO2转录的分子机制

利用荧光素酶报告基因检测Oatp1c1和Dio2启动子活性;通过siRNA或过表达E4BP4检测其对启动子活性和OATP1C1/DIO2表达的影响;ChIP检测E4BP4在Oatp1c1和Dio2启动子上的结合。

6

评估CRY1激动剂KL201和T3补充的治疗效果

验证靶向CRY1或补充T3能否改善焦虑样行为

在CRS小鼠中给予KL201(5 mg/kg,腹腔注射),或在Cry1-/-小鼠中给予T3(0.1 mg/kg),通过行为学测试和分子检测评估焦虑表型和相关基因表达变化。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

产品清单

实验环节名称品牌货号
抗BDNF抗体Affinity BiosciencesDF6387
抗CREB抗体Affinity BiosciencesAF6188
抗OATP1C1抗体ImmunoWay BiotechnologyYT3221
抗DIO2抗体ImmunoWay BiotechnologyYN2888
抗CRY1抗体Proteintech13474-1-AP
抗E4BP4抗体Proteintech11773-1-AP
抗GAPDH抗体Proteintech10494-1-AP
抗兔IgG抗体ProteintechSA00001-2
KL201MedChemExpressHY-134194
SimpleChIP® Plus酶法染色质IP试剂盒Cell Signaling Technology9005
Jetprime转染试剂Polyplus114-15
皮质酮ApexBio TechnologyB7469
T3、T4、rT3和TSH的ELISA试剂盒Jingmei Biotechnology--
Trizol试剂Vazyme--
SYBR Green预混液Vazyme--
pcDNA3.1载体Transheep Technologies--
pcDNA3.1-Cry1质粒Transheep Technologies--
pcDNA3.1-CRY1质粒Transheep Technologies--
pcDNA3.1-E4bp4质粒Transheep Technologies--
siRNAIGE Biotechnology--

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
动物模型
Cry1-/-小鼠基因型,C57BL/6背景;WT小鼠来源(广州中医药大学);小鼠年龄(8-12周龄用于CRS);光照周期12/12小时
阅读提示:Materials and Methods 2.2 Animals
慢性束缚应激(CRS)
束缚时间(2小时/天)、天数(10天)、小鼠性别(雄性)
阅读提示:Materials and Methods 2.3 Chronic restraint stress
药物处理
KL201剂量(5 mg/kg)、给药方式(腹腔注射)、给药时间(ZT10)、给药天数(10天);T3剂量(0.1 mg/kg)、给药方式(腹腔注射)、给药天数(7天)
阅读提示:Materials and Methods 2.4 KL201 treatment; Figure 6 legend
行为学测试
EPM测试时间(5分钟)、OFT测试时间(10分钟)、MBB测试时间(30分钟)、LDB测试时间(6分钟);FCT条件(CS: 65 dB, 4000 Hz, 30s; US: 0.4 mA, 2s; 5次重复)
阅读提示:Materials and Methods 2.5 Behavioral tests
细胞实验
HT-22和SH-SY5Y细胞来源(Procell)、培养条件(DMEM+10% FBS、MEM+15% FBS)、CORT浓度(100 μM)和处理时间(24小时)
阅读提示:Materials and Methods 2.9 Cell culture and transfection; 2.10 Corticosterone treatment
分子检测
qPCR引物序列(Table 1)、Western blot一抗稀释比例(如anti-CRY1 1:500等)
阅读提示:Materials and Methods 2.12 qPCR; 2.13 Western blotting; Table 1